We Offer Worldwide Shipping
Login Wishlist

Lansoprazole

$64

  • Brand : BIOFRON

  • Catalogue Number : BN-O1021

  • Specification : 98%(HPLC)

  • CAS number : 103577-45-3

  • Formula : C16H14F3N3O2S

  • Molecular Weight : 369.36

  • PUBCHEM ID : 3883

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1021

Analysis Method

Specification

98%(HPLC)

Storage

-20℃

Molecular Weight

369.36

Appearance

Powder

Botanical Source

Structure Type

Category

SMILES

CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F

Synonyms

2-({[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl}sulfinyl)-1H-benzimidazole/Ogast/Agopton/Lanz/1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-/Promp/Limpidex/2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole/Ulpax/Takepron/2-[({3-methyl-4-[(2,2,2-trifluoroethyl)oxy]pyridin-2-yl}methyl)sulfinyl]-1H-benzimidazole/Zoton/2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole/2-({[3-Methyl-4-(2,2,2-trifluorethoxy)pyridin-2-yl]methyl}sulfinyl)-1H-benzimidazol/Lansox/Prevacid/Ketian/Lansoprazole/Lanzor/Lancid

IUPAC Name

Density

1.5±0.1 g/cm3

Solubility

Flash Point

289.9±32.9 °C

Boiling Point

555.8±60.0 °C at 760 mmHg

Melting Point

178-182°C dec.

InChl

InChI=1S/C27H40O2/c1-20(2)10-7-11-21(3)12-8-13-22(4)14-9-16-27(6)17-15-24-19-25(28)18-23(5)26(24)29-27/h10,12,14,18-19,28H,7-9,11,13,15-17H2,1-6H3/b21-12+,22-14+/t27-/m1/s1

InChl Key

MJIHNNLFOKEZEW-UHFFFAOYSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:103577-45-3) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

30000342

Title

Lansoprazole

PMID

15281616

Abstract

An analytical method based on liquid chromatography with positive ion electrospray ionization (ESI) coupled to tandem mass spectrometry detection was developed for the determination of pantoprazole (CAS 102625-70-7) in human plasma using lansoprazole (CAS 103577-45-3) as the internal standard. The analyte and internal standard were extracted from the plasma samples by liquid/liquid extraction using diethyl-ether/dichloromethane (70:30; v/v) and chromatographed on a C8 analytical column. The mobile phase consisted of acetonitrile/ water/methanol (57:25:18; v/v/v) + 10 mmol/l acetic acid + 20 mmol/l ammonium acetate. The method has a chromatographic total run time of 4.5 min and was linear within the range 5.0-5,000 ng/ mL. Detection was performed on a triple quadrupole tandem mass spectrometer by Multiple Reaction Monitoring (MRM). The intra- and inter-run precisions calculated from quality control (QC) samples were 4.2 % and 3.2 %, respectively. The accuracies as determined from QC samples were -5.0 % (intra-run) and 2.0 % (inter-run). The method herein described was employed in a bioequivalence study of two tablet formulations of pantoprazole.

Title

Determination of Pantoprazole in Human Plasma by LC-MS-MS Using Lansoprazole as Internal Standard

Author

Osmair Peres 1, Celso H Oliveira, Rafael E Barrientos-Astigarraga, Vinicius M Rezende, Gustavo D Mendes, Gilberto de Nucci

Publish date

2004

PMID

21650084

Abstract

Prasugrel (CAS 150322-43-3), an inhibitor of platelet activation and aggregation, is indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome. If a proton pump inhibitor is co-administered with prasugrel, a pH dependent salt-to-base conversion rate of prasugrel could become clinically meaningful. In an open-label, randomized, four-period, 2 x two-way crossover study, the relative bioavailability of tablets containing prasugrel free base compared to prasugrel hydrochloride (originator product) both in the presence and in the absence of the proton pump inhibitor lansoprazole (CAS 103577-45-3) was investigated. In the absence of lansoprazole, the extent of absorption (AUC) of prasugrel free base was about 8-9% lower, while the rate of absorption (Cmax) after administration of prasugrel free base was 20% lower when compared to prasugrel hydrochloride. When lansoprazole was used to raise the pH level in the upper gastro-intestinal tract, AUC was decreased by 25% after administration of prasugrel hydrochloride and by 41% after prasugrel free base. In addition, the peak plasma levels were decreased by 52% and 72%, respectively (geometric means). The relative bioavailability of the prasugrel free base compared to prasugrel hydrochloride, both in the presence and in the absence of the proton pump inhibitor lansoprazole, differs so much that most probably a generic formulation containing prasugrel free base will not be equivalent in all aspects to the originator product.

Title

Relative Bioavailability of Prasugrel Free Base in Comparison to Prasugrel Hydrochloride in the Presence and in the Absence of a Proton Pump Inhibitor

Publish date

2011


Description :

Empty ...